En undersøgelse til at sammenligne Blinatumomab alene med Blinatumomab med Nivolumab hos patienter diagnosticeret med første tilbagefald B-celle akut lymfatisk leukæmi (B-ALL)
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
- Procedure: Bone Marrow Biopsy
- Biologisk: Nivolumab
- Biologisk: Blinatumomab
- Procedure: Bone Marrow Aspiration
- Procedure: Lumbar Puncture
- Medicin: Mercaptopurine
- Medicin: Pegaspargase
- Medicin: Calaspargase Pegol
- Medicin: Dexamethasone
- Medicin: Asparaginase Erwinia chrysanthemi
- Medicin: Cytarabine
- Procedure: Biospecimen Collection
- Medicin: Hydrocortisone Sodium Succinate
- Medicin: Methotrexate
- Stråling: 3-Dimensional Conformal Radiation Therapy
- Medicin: Vincristine Sulfate
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To compare event free survival post reinduction (EFS PR) between blinatumomab vs. blinatumomab/nivolumab in Group 4 patients aged ≥ 1 to <31 years old with first relapse of CD19+ B ALL.
II. To compare EFS PR (EFS post-reinduction) between consolidation with blinatumomab vs. blinatumomab/nivolumab in Group 3 patients aged >= 1 to < 31 years old with first relapse of CD19+ B ALL.
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerability of blinatumomab/nivolumab in patients aged >= 1 to < 31 years old with first relapse of CD19+ B ALL.
EXPLORATORY OBJECTIVES:
I. In Group 4 patients, compare EFS PR between blinatumomab monotherapy and blinatumomab/nivolumab arms as compared to similar patients treated on the predecessor trial AALL1331.
II. In Group 4 patients, compare toxicity as defined by grade 3 or greater adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab.
III. In Group 4 patients, compare MRD negative second remission (Rem-2) rate after the first cycle of immunotherapy between blinatumomab monotherapy and blinatumomab/nivolumab arms.
IV. In patients with Down syndrome (DS) with first relapse of B-ALL, describe the safety, tolerability and efficacy (as defined by MRD negative second remission, Rem-2) after up to two cycles of blinatumomab/nivolumab.
V. With each Group, perform subset analyses of EFS and overall survival (OS) based on features including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count at first relapse.
OUTLINE:
Patients >= 18 years old with marrow +/- extramedullary (EM) relapse of any duration after initial diagnosis, or patients < 18 years old with marrow +/- EM relapse < 24 months after initial diagnosis are assigned to Group 1. Patients < 18 years old with marrow +/- EM relapse >= 24 months from initial diagnosis, or all isolated extramedullary (IEM) relapses >= 1 to < 31 years old are assigned to Groups 2-3 re-induction. Patients with DS are assigned to Arm G. NOTE: Patients in Group 1 and DS patients with white blood cells (WBC) >= 30,000/uL, CNS 2/3 disease, or testicular disease must first receive 1 of 3 pre-immunotherapy treatments.
Starting with amendment 4C (9/19/2024), patients with DS are assigned to group 3 or 4. Patients < 18 years with bone marrow first relapse ≥ 36 months from initial diagnosis with MRD <0.1% after VXLD reinduction or with isolated CNS/testicular extramedullary relapse occurring ≥ 18 months from initial diagnosis with MRD <0.1% after VXLD reinduction are assigned to group 3. Patients who do not meet criteria for group 3 will be assigned to group 4. Patients with Down syndrome ≥ 1 to < 31 years of age with first bone marrow relapse of B ALL are assigned to arm G.
PRE-IMMUNOTHERAPY TREATMENT FOR PATIENTS WITH WBC >= 30,000/uL (CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G) : Patients receive methotrexate (MTX) intrathecally (IT) or cytarabine IT or intrathecal triple therapy (ITT) consisting of MTX, hydrocortisone sodium succinate, and cytarabine IT at the time of diagnostic lumbar puncture (LP) or on day 1 (if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy). Patients also receive dexamethasone intravenously (IV) or orally (PO) twice daily (BID) on days 1-5, vincristine sulfate via infusion or IV push over 1 minute on day 1. Patients with DS also receive leucovorin calcium PO or IV every 6 hours (q6h) for 2 doses on day 2 or at 24 and 30 hours after each IT administration. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 8 and no later than Day 15.
PRE-IMMUNOTHERAPY TREATMENT FOR CNS 2/3 DISEASE (CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G): Patients receive MTX IT or cytarabine IT twice weekly (Q2W) for 5-7 doses or Intrathecal Triple Therapy (ITT) IT Q2W for 3-4 doses until patient is CNS 1. Patients with DS also receive leucovorin calcium PO or IV q6h for 2 doses at 24 and 30 hours after each IT administration. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 15 and no later than Day 24.
PRE-IMMUNOTHERAPY TREATMENT FOR TESTICULAR DISEASE(CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G): Patients receive MTX IT, cytarabine IT, or ITT IT on days 1 and 15 (day 1 may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy). Patients with DS also receive leucovorin calcium PO or IV q6h for 2 doses on days 2 and 16 or at 24 and 30 hours after each IT administration. Males with testicular disease at relapse undergo radiation once daily (QD) for a total of 12 fractions over 12 days. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 15 and no later than Day 22.
GROUP 1 (CLOSED TO ACCRUAL 9/19/2024): Patients are randomized to Arm A or Arm B.
ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
ARM B: Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
GROUPS 2-4 VXLD REINDUCTION: Patients receive vincristine sulfate via infusion or IV push over 1 minute on days 1, 8, 15, and 22, dexamethasone PO or IV on days 1-14, doxorubicin hydrochloride IV over 3-15 minutes on day 1, MTX IT on days 1, 8, and 29 (day 1 IT may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of this cycle) (days 8 and 29 for CNS 1 patients at relapse only), pegaspargase intramuscularly (IM) or IV over 1-2 hours on days 2 and 16 or calaspargase IV over 1-2 hours on day 2 (for patients ≤ 22 years), cytarabine IT on days 4 and 11 (CNS 2 patients at relapse only), then Q2W until 3 consecutive samples are clear of blasts, and ITT IT on days 8, 15, 22, and 29 (CNS 3 patients at relapse only). Patients with CNS 2 disease at relapse that does not resolve to CNS 1 by day 15 receive maintenance chemoradiation before initiation of maintenance. Treatment continues in the absence of disease progression or unacceptable toxicity.
GROUP 2 (CLOSED TO ACCRUAL 9/19/2024): The following patients are randomized to Arm C or Arm D: 1) >= 1 to < 31 years old, IEM relapse < 18 months from diagnosis, regardless of MRD after Re-Induction. 2) < 18 years old with marrow relapse >= 24 to < 36 months from diagnosis regardless of MRD after Re-Induction, 3) >= 1 to < 31 years old, IEM relapse >= 18 months, and MRD >= 0.1% after Re-Induction, 4) < 18 years old with marrow relapse >= 36 months, and MRD >= 0.1% after Re-Induction.
ARM C: Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and MTX IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal MTX is given < 7 days prior to the start of cycle 1 ). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
ARM D: Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
GROUP 3: Patients are randomized to Arm E or Arm F.
ARM E:
IMMUNOTHERAPY CYCLES 1-2: Patients receive dexamethasone PO or IV on day 1 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, and MTX IT on days 1 and 15 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Immunotherapy cycles 1-2 alternate with Consolidation cycles 1-2.
CONSOLIDATION: Patients receive dexamethasone PO or IV on days 1-5, methotrexate IV, over 24 hours, on days 8 and 22, methotrexate IT on days 8 and 22 (CNS 1/2 at relapse only) or ITT IT on days 8 and 22 (CNS 3 at relapse only).
INTENSIFICATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, mercaptopurine PO on days 1-42, methotrexate IV over 24 hours on days 8 and 22, cytarabine IV, over 3 hours on days 43 and 44, asparaginase erwinia chrysanthemi IM on day 44, methotrexate IT on days 1 and 43 (CNS 1/2 at relapse only) or ITT IT on days 1 and 43 (CNS 3 at relapse only).
IMMUNOTHERAPY CYCLE 3: Patients receive blinatumomab IV via continuous infusion on days 1-28, and MTX IT on days 1 and 15 (CNS 1/2 at relapse only) or ITT IT on days 1 and 15 (CNS 3 at relapse only).
MAINTENANCE: Patients receive dexamethasone PO BID on days 1-5, 29-33, and 57-61, vincristine sulfate IV push over 1 minute or via infusion on days 1, 29, and 57, mercaptopurine PO on days 1-84, MTX IT on day 1 (only for patients who did not receive cranial radiation), and MTX PO on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 (Omit day 1 for patients receiving day 1 IT MTX). Treatment repeats every 12 weeks for 2 years from the start of Re-Induction therapy in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CHEMORADIATION: Prior to the first cycle of maintenance therapy, patients with CNS 3 at relapse or CNS 2 at relapse that did not resolve to CNS 1 by day 15 of VXLD Reinduction receive dexamethasone PO BID on days 1-7 and 15-21, vincristine sulfate IV push over 1 minute or via infusion on days 1, 8, and 15, and pegaspargase IM or IV over 1-2 hours or calaspargase IV over 1-2 hours on day 1. Patients with CNS 3 and isolated CNS relapse undergo cranial radiation in the form of 3-dimensional (D)-conformal radiation therapy (CRT) over 5 days per week for a total of 10 treatments.
ARM F:
IMMUNOTHERAPY CYCLES 1-2: Patients receive dexamethasone PO or IV on day 1 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and on days 1 of cycles 2 and 3, and MTX IT on days 1 and 15 (CNS 1/2 patients at relapse only)(day 1 may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle) or , ITT IT on days 1 and 15 (CNS 3 patients at relapse only) (day 1 may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Immunotherapy cycles 1-2 alternate with Consolidation cycles 1-2.
CONSOLIDATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, methotrexate IV, over 24 hours, on days 8 and 22, methotrexate IT on days 8 and 22 (CNS 1/2 at relapse only) or ITT IT on days 8 and 22 (CNS 3 at relapse only).
INTENSIFICATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, mercaptopurine PO on days 1-42, methotrexate IV over 24 hours on days 8 and 22, cytarabine IV, over 3 hours on days 43 and 44, asparaginase erwinia chrysanthemi IM on day 44, methotrexate IT on days 1 and 43 (CNS 1/2 at relapse only) or ITT IT on days 1 and 43 (CNS 3 at relapse only).
IMMUNOTHERAPY CYCLE 3: Patients receive blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on day 1 and MTX IT on days 1 and 15 (CNS 1/2 at relapse only) or ITT IT on days 1 and 15 (CNS 3 at relapse only).
MAINTENANCE: Patients receive dexamethasone PO BID on days 1-5, 29-33, and 57-61, vincristine sulfate IV push over 1 minute or via infusion on days 1, 29, and 57, mercaptopurine PO on days 1-84, MTX IT on day 1 (only for patients who did not receive cranial radiation), and MTX PO on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 (Omit for patients receiving day 1 IT MTX). Treatment repeats every 12 weeks for 2 years from the start of Re-Induction therapy in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CHEMORADIATION: Prior to the first cycle of maintenance therapy, patients with CNS 3 at relapse or CNS 2 at relapse that did not resolve to CNS 1 by day 15 of VXLD Reinduction receive dexamethasone PO BID on days 1-7 and 15-21, vincristine sulfate IV push over 1 minute or via infusion on days 1, 8, and 15, and pegaspargase IM or IV over 1-2 hours or calaspargase IV over 1-2 hours on day 1. Patients with CNS 3 and isolated CNS relapse undergo cranial radiation in the form of 3-dimensional (D)-conformal radiation therapy (CRT) over 5 days per week for a total of 10 treatments.
GROUP 4: Patients are randomized to arm H or arm I.
ARM H: Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 36 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
ARM I: Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS 1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 36 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
ARM G (DS PATIENTS): Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle 2, and MTX IT (for patients with CNS 1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD <0.01% at the end of Cycle 1 may stop study treatment at the discretion of the treating physician.
Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study.
After completion of study treatment, patients are followed up every 3 months for 1 year.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Australien, 2310
- Suspenderet
- John Hunter Children's Hospital
-
Randwick, New South Wales, Australien, 2031
- Suspenderet
- Sydney Children's Hospital
-
Westmead, New South Wales, Australien, 2145
- Suspenderet
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australien, 4101
- Suspenderet
- Queensland Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australien, 6009
- Suspenderet
- Perth Children's Hospital
-
-
-
-
-
Québec, Canada, G1V 4G2
- Rekruttering
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Ledende efterforsker:
- Bruno Michon
-
Kontakt:
- Site Public Contact
- Telefonnummer: 418-525-4444
- E-mail: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Suspenderet
- Alberta Children's Hospital
-
Edmonton, Alberta, Canada, T6G 2B7
- Rekruttering
- University of Alberta Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 780-407-8798
- E-mail: pedsoncologyresearch@ahs.ca
-
Ledende efterforsker:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Suspenderet
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Rekruttering
- CancerCare Manitoba
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-561-1026
- E-mail: ctu_web@cancercare.mb.ca
-
Ledende efterforsker:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Rekruttering
- Janeway Child Health Centre
-
Ledende efterforsker:
- Lisa A. Goodyear
-
Kontakt:
- Site Public Contact
- Telefonnummer: 709-777-8727
- E-mail: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Rekruttering
- IWK Health Centre
-
Kontakt:
- Site Public Contact
- Telefonnummer: 902-470-8520
- E-mail: Research@iwk.nshealth.ca
-
Ledende efterforsker:
- Chelsea Ash
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Rekruttering
- The Montreal Children's Hospital of the MUHC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 514-412-4445
- E-mail: info@thechildren.com
-
Ledende efterforsker:
- Stephanie Mourad
-
Montreal, Quebec, Canada, H3T 1C5
- Rekruttering
- Centre Hospitalier Universitaire Sainte-Justine
-
Ledende efterforsker:
- Monia Marzouki
-
Kontakt:
- Site Public Contact
- Telefonnummer: 514-345-4931
- E-mail: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Rekruttering
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Kontakt:
- Site Public Contact
- Telefonnummer: 819-820-6480
- E-mail: crcinformation.chus@ssss.gouv.qc.ca
-
Ledende efterforsker:
- Stephanie Vairy
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- Rekruttering
- Children's Hospital of Alabama
-
Kontakt:
- Site Public Contact
- Telefonnummer: 205-638-9285
- E-mail: oncologyresearch@peds.uab.edu
-
Ledende efterforsker:
- Matthew A. Kutny
-
Mobile, Alabama, Forenede Stater, 36604
- Rekruttering
- USA Health Strada Patient Care Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-388-8721
-
Ledende efterforsker:
- Hamayun Imran
-
-
Alaska
-
Anchorage, Alaska, Forenede Stater, 99508
- Rekruttering
- Providence Alaska Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 907-212-6871
- E-mail: AKPAMC.OncologyResearchSupport@providence.org
-
Ledende efterforsker:
- Brenda J. Wittman
-
-
Arizona
-
Kingman, Arizona, Forenede Stater, 86401
- Suspenderet
- Kingman Regional Medical Center
-
Mesa, Arizona, Forenede Stater, 85202
- Rekruttering
- Banner Children's at Desert
-
Kontakt:
- Site Public Contact
- Telefonnummer: 480-412-3100
-
Ledende efterforsker:
- Joseph C. Torkildson
-
Phoenix, Arizona, Forenede Stater, 85016
- Rekruttering
- Phoenix Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 602-546-0920
-
Ledende efterforsker:
- Dana B. Salzberg
-
Tucson, Arizona, Forenede Stater, 85719
- Rekruttering
- Banner University Medical Center - Tucson
-
Kontakt:
- Site Public Contact
- E-mail: UACC-IIT@uacc.arizona.edu
-
Ledende efterforsker:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72202-3591
- Rekruttering
- Arkansas Children's Hospital
-
Ledende efterforsker:
- Michael W. Bishop
-
Kontakt:
- Site Public Contact
- Telefonnummer: 501-364-7373
-
-
California
-
Anaheim, California, Forenede Stater, 92806
- Suspenderet
- Kaiser Permanente-Anaheim
-
Arroyo Grande, California, Forenede Stater, 93420
- Suspenderet
- PCR Oncology
-
Bellflower, California, Forenede Stater, 90706
- Suspenderet
- Kaiser Permanente-Bellflower
-
Downey, California, Forenede Stater, 90242
- Rekruttering
- Kaiser Permanente Downey Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 626-564-3455
-
Ledende efterforsker:
- Robert M. Cooper
-
Duarte, California, Forenede Stater, 91010
- Aktiv, ikke rekrutterende
- City of Hope Comprehensive Cancer Center
-
Fontana, California, Forenede Stater, 92335
- Rekruttering
- Kaiser Permanente-Fontana
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Ledende efterforsker:
- Robert M. Cooper
-
Loma Linda, California, Forenede Stater, 92354
- Rekruttering
- Loma Linda University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 909-558-4050
-
Ledende efterforsker:
- Albert Kheradpour
-
Long Beach, California, Forenede Stater, 90806
- Rekruttering
- Miller Children's and Women's Hospital Long Beach
-
Kontakt:
- Site Public Contact
- Telefonnummer: 562-933-5600
-
Ledende efterforsker:
- Jacqueline N. Casillas
-
Los Angeles, California, Forenede Stater, 90027
- Rekruttering
- Children's Hospital Los Angeles
-
Kontakt:
- Site Public Contact
- Telefonnummer: 323-361-4110
-
Ledende efterforsker:
- Jamie L. Stokke
-
Los Angeles, California, Forenede Stater, 90048
- Rekruttering
- Cedars-Sinai Medical Center
-
Ledende efterforsker:
- Nicole M. Baca
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-423-2133
- E-mail: Cancer.trial.info@cshs.org
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- Mattel Children's Hospital UCLA
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-825-6708
-
Ledende efterforsker:
- Satiro N. De Oliveira
-
Los Angeles, California, Forenede Stater, 90027
- Suspenderet
- Kaiser Permanente Los Angeles Medical Center
-
Madera, California, Forenede Stater, 93636
- Rekruttering
- Valley Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 559-353-3000
- E-mail: Research@valleychildrens.org
-
Ledende efterforsker:
- Ruetima Titapiwatanakun
-
Oakland, California, Forenede Stater, 94611
- Rekruttering
- Kaiser Permanente-Oakland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-mail: Kpoct@kp.org
-
Ledende efterforsker:
- Aarati V. Rao
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- Children's Hospital of Orange County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 714-509-8646
- E-mail: oncresearch@choc.org
-
Ledende efterforsker:
- Elyssa M. Rubin
-
Palo Alto, California, Forenede Stater, 94304
- Rekruttering
- Lucile Packard Children's Hospital Stanford University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-694-0012
- E-mail: ccto-office@stanford.edu
-
Ledende efterforsker:
- Jay Michael S. Balagtas
-
Sacramento, California, Forenede Stater, 95817
- Rekruttering
- University of California Davis Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 916-734-3089
-
Ledende efterforsker:
- Marcio H. Malogolowkin
-
Sacramento, California, Forenede Stater, 95816
- Rekruttering
- Sutter Medical Center Sacramento
-
Kontakt:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Ledende efterforsker:
- Sandra Baril
-
San Diego, California, Forenede Stater, 92120
- Rekruttering
- Kaiser Permanente-San Diego Zion
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Ledende efterforsker:
- Robert M. Cooper
-
San Diego, California, Forenede Stater, 92123
- Rekruttering
- Rady Children's Hospital - San Diego
-
Kontakt:
- Site Public Contact
- Telefonnummer: 858-966-5934
-
Ledende efterforsker:
- William D. Roberts
-
San Francisco, California, Forenede Stater, 94158
- Rekruttering
- UCSF Medical Center-Mission Bay
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-3222
- E-mail: cancertrials@ucsf.edu
-
Ledende efterforsker:
- Karen R. Rabin
-
Torrance, California, Forenede Stater, 90502
- Aktiv, ikke rekrutterende
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- Children's Hospital Colorado
-
Ledende efterforsker:
- Kelly E. Faulk
-
Kontakt:
- Site Public Contact
- Telefonnummer: 303-764-5056
- E-mail: josh.b.gordon@nsmtp.kp.org
-
Denver, Colorado, Forenede Stater, 80218
- Rekruttering
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 303-832-2344
- E-mail: PSGResearchSharedMailbox@HCAHealthcare.com
-
Ledende efterforsker:
- Florence Choo
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06106
- Rekruttering
- Connecticut Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 860-545-9981
-
Ledende efterforsker:
- Michael S. Isakoff
-
-
Delaware
-
Wilmington, Delaware, Forenede Stater, 19803
- Rekruttering
- Alfred I duPont Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Ledende efterforsker:
- Emi H. Caywood
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Rekruttering
- Children's National Medical Center
-
Ledende efterforsker:
- Jeffrey S. Dome
-
Kontakt:
- Site Public Contact
- Telefonnummer: 202-476-2800
- E-mail: OncCRC_OnCall@childrensnational.org
-
Washington D.C., District of Columbia, Forenede Stater, 20007
- Rekruttering
- MedStar Georgetown University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 202-444-2223
-
Ledende efterforsker:
- Caileigh Pudela
-
-
Florida
-
Fort Myers, Florida, Forenede Stater, 33908
- Rekruttering
- Golisano Children's Hospital of Southwest Florida
-
Kontakt:
- Site Public Contact
- Telefonnummer: 239-343-5333
- E-mail: molly.arnstrom@leehealth.org
-
Ledende efterforsker:
- Emad K. Salman
-
Gainesville, Florida, Forenede Stater, 32610
- Rekruttering
- UF Health Cancer Institute - Gainesville
-
Ledende efterforsker:
- Brian Stover
-
Kontakt:
- Site Public Contact
- Telefonnummer: 352-273-8010
-
Hollywood, Florida, Forenede Stater, 33021
- Rekruttering
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 954-265-1847
- E-mail: OHR@mhs.net
-
Ledende efterforsker:
- Iftikhar Hanif
-
Jacksonville, Florida, Forenede Stater, 32207
- Rekruttering
- Nemours Children's Clinic-Jacksonville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Ledende efterforsker:
- Emi H. Caywood
-
Orlando, Florida, Forenede Stater, 32806
- Rekruttering
- Arnold Palmer Hospital for Children
-
Ledende efterforsker:
- Jaime M. Libes-Bander
-
Kontakt:
- Site Public Contact
- Telefonnummer: 321-841-5357
- E-mail: Jennifer.spinelli@orlandohealth.com
-
Orlando, Florida, Forenede Stater, 32827
- Rekruttering
- Nemours Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-mail: Allison.bruce@nemours.org
-
Ledende efterforsker:
- Emi H. Caywood
-
Orlando, Florida, Forenede Stater, 32803
- Rekruttering
- AdventHealth Orlando
-
Kontakt:
- Site Public Contact
- Telefonnummer: 407-303-2090
- E-mail: FH.Cancer.Research@flhosp.org
-
Ledende efterforsker:
- Fouad M. Hajjar
-
Pensacola, Florida, Forenede Stater, 32504
- Suspenderet
- Sacred Heart Hospital
-
Pensacola, Florida, Forenede Stater, 32504
- Rekruttering
- Nemours Children's Clinic - Pensacola
-
Kontakt:
- Site Public Contact
- E-mail: helpdesk@childrensoncologygroup.org
-
Ledende efterforsker:
- Jeffrey H. Schwartz
-
St. Petersburg, Florida, Forenede Stater, 33701
- Rekruttering
- Johns Hopkins All Children's Hospital
-
Ledende efterforsker:
- Jennifer L. Mayer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 727-767-4784
- E-mail: Ashley.Repp@jhmi.edu
-
Tampa, Florida, Forenede Stater, 33606
- Rekruttering
- Tampa General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 813-844-7829
- E-mail: syapchanyk@tgh.org
-
Ledende efterforsker:
- Andrew J. Galligan
-
Tampa, Florida, Forenede Stater, 33607
- Rekruttering
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 813-357-0849
- E-mail: jennifer.manns@baycare.org
-
Ledende efterforsker:
- Don E. Eslin
-
West Palm Beach, Florida, Forenede Stater, 33407
- Rekruttering
- Saint Mary's Medical Center
-
Ledende efterforsker:
- Matthew D. Ramirez
-
Kontakt:
- Site Public Contact
- Telefonnummer: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30329
- Rekruttering
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Ledende efterforsker:
- Waitman K. Aumann
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-785-0232
- E-mail: Olivia.Floyd@choa.org
-
Savannah, Georgia, Forenede Stater, 31404
- Rekruttering
- Memorial Health University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 912-350-7887
- E-mail: Lorraine.OHara@hcahealthcare.com
-
Ledende efterforsker:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96826
- Rekruttering
- Kapiolani Medical Center for Women and Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-983-6090
-
Ledende efterforsker:
- Wade T. Kyono
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83712
- Rekruttering
- Saint Luke's Cancer Institute - Boise
-
Ledende efterforsker:
- Martha M. Pacheco
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-mail: eslinget@slhs.org
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Lurie Children's Hospital-Chicago
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-880-4562
-
Ledende efterforsker:
- Jenna Rossoff
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Ledende efterforsker:
- Gabrielle Lapping-Carr
-
Chicago, Illinois, Forenede Stater, 60612
- Rekruttering
- University of Illinois
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Ledende efterforsker:
- Dipti S. Dighe
-
Maywood, Illinois, Forenede Stater, 60153
- Rekruttering
- Loyola University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 708-226-4357
-
Ledende efterforsker:
- Eugene Suh
-
Peoria, Illinois, Forenede Stater, 61637
- Rekruttering
- OSF Children's Hospital of Illinois
-
Ledende efterforsker:
- Prerna Kumar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-624-4945
- E-mail: ChildrensHospitalofIllinois@osfhealthcare.org
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Rekruttering
- Riley Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-248-1199
-
Ledende efterforsker:
- Sandeep Batra
-
Indianapolis, Indiana, Forenede Stater, 46260
- Rekruttering
- Ascension Saint Vincent Indianapolis Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 317-338-2194
- E-mail: research@stvincent.org
-
Ledende efterforsker:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, Forenede Stater, 50309
- Rekruttering
- Blank Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-8912
- E-mail: samantha.mallory@unitypoint.org
-
Ledende efterforsker:
- Samantha L. Mallory
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- University of Iowa/Holden Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-237-1225
-
Ledende efterforsker:
- Andrew P. Groves
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- Rekruttering
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
Ledende efterforsker:
- James T. Badgett
-
Louisville, Kentucky, Forenede Stater, 40202
- Rekruttering
- Norton Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-629-5500
- E-mail: CancerResource@nortonhealthcare.org
-
Ledende efterforsker:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70118
- Rekruttering
- Children's Hospital New Orleans
-
Ledende efterforsker:
- Maria C. Velez-Yanguas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-894-5377
-
New Orleans, Louisiana, Forenede Stater, 70121
- Aktiv, ikke rekrutterende
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Forenede Stater, 04401
- Rekruttering
- Eastern Maine Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-973-4274
-
Ledende efterforsker:
- Daniel L. Callaway
-
Scarborough, Maine, Forenede Stater, 04074
- Rekruttering
- Maine Children's Cancer Program
-
Ledende efterforsker:
- Eric C. Larsen
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Rekruttering
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Ledende efterforsker:
- Stacy L. Cooper
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-955-8804
- E-mail: jhcccro@jhmi.edu
-
Baltimore, Maryland, Forenede Stater, 21215
- Rekruttering
- Sinai Hospital of Baltimore
-
Ledende efterforsker:
- Jason M. Fixler
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-601-9083
-
Bethesda, Maryland, Forenede Stater, 20889-5600
- Suspenderet
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02111
- Aktiv, ikke rekrutterende
- Tufts Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- C S Mott Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-865-1125
-
Ledende efterforsker:
- Joshua W. Goldman
-
Battle Creek, Michigan, Forenede Stater, 49017
- Suspenderet
- Bronson Battle Creek
-
Dearborn, Michigan, Forenede Stater, 48124
- Suspenderet
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Forenede Stater, 48201
- Suspenderet
- Children's Hospital of Michigan
-
East Lansing, Michigan, Forenede Stater, 48823
- Aktiv, ikke rekrutterende
- Michigan State University
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Suspenderet
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Rekruttering
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Ledende efterforsker:
- Kathleen Y. Butler
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Suspenderet
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Forenede Stater, 49007
- Rekruttering
- Bronson Methodist Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Ledende efterforsker:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Forenede Stater, 49007
- Suspenderet
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Forenede Stater, 49048
- Suspenderet
- Beacon Kalamazoo
-
Muskegon, Michigan, Forenede Stater, 49444
- Suspenderet
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Forenede Stater, 49120
- Suspenderet
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Forenede Stater, 49444
- Suspenderet
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Forenede Stater, 49677
- Suspenderet
- Corewell Health Reed City Hospital
-
Royal Oak, Michigan, Forenede Stater, 48073
- Rekruttering
- Corewell Health Children's
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Ledende efterforsker:
- Marie V. Nelson
-
Royal Oak, Michigan, Forenede Stater, 48073
- Suspenderet
- Corewell Health William Beaumont University Hospital
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Suspenderet
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Suspenderet
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, Forenede Stater, 49684
- Suspenderet
- Munson Medical Center
-
Troy, Michigan, Forenede Stater, 48085
- Suspenderet
- Corewell Health Beaumont Troy Hospital
-
Wyoming, Michigan, Forenede Stater, 49519
- Suspenderet
- University of Michigan Health - West
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55404
- Rekruttering
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Ledende efterforsker:
- Michael K. Richards
-
Kontakt:
- Site Public Contact
- Telefonnummer: 612-813-5913
- E-mail: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, Forenede Stater, 55455
- Rekruttering
- University of Minnesota/Masonic Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 612-624-2620
-
Ledende efterforsker:
- Peter M. Gordon
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
- Rekruttering
- University of Mississippi Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 601-815-6700
-
Ledende efterforsker:
- Amanda Strobel
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64108
- Rekruttering
- Children's Mercy Hospitals and Clinics
-
Ledende efterforsker:
- Keith J. August
-
Kontakt:
- Site Public Contact
- Telefonnummer: 816-302-6808
- E-mail: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Ledende efterforsker:
- Kristin Zorn
-
St Louis, Missouri, Forenede Stater, 63141
- Rekruttering
- Mercy Hospital Saint Louis
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-251-7066
-
Ledende efterforsker:
- Robin D. Hanson
-
St Louis, Missouri, Forenede Stater, 63104
- Rekruttering
- Cardinal Glennon Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-268-4000
-
Ledende efterforsker:
- William S. Ferguson
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
- Rekruttering
- Children's Hospital and Medical Center of Omaha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-955-3949
-
Ledende efterforsker:
- Jill C. Beck
-
Omaha, Nebraska, Forenede Stater, 68198
- Rekruttering
- University of Nebraska Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-mail: unmcrsa@unmc.edu
-
Ledende efterforsker:
- Jill C. Beck
-
-
Nevada
-
Carson City, Nevada, Forenede Stater, 89703
- Suspenderet
- Carson Tahoe Regional Medical Center
-
Henderson, Nevada, Forenede Stater, 89052
- Suspenderet
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, Forenede Stater, 89052
- Suspenderet
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, Forenede Stater, 89052
- Suspenderet
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, Forenede Stater, 89074
- Suspenderet
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Las Vegas, Nevada, Forenede Stater, 89135
- Rekruttering
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-mail: research@sncrf.org
-
Ledende efterforsker:
- Joseph L. Lasky
-
Las Vegas, Nevada, Forenede Stater, 89144
- Rekruttering
- Summerlin Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-mail: research@sncrf.org
-
Ledende efterforsker:
- Joseph L. Lasky
-
Las Vegas, Nevada, Forenede Stater, 89103
- Suspenderet
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Forenede Stater, 89109
- Suspenderet
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Forenede Stater, 89128
- Suspenderet
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, Forenede Stater, 89128
- Suspenderet
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, Forenede Stater, 89128
- Suspenderet
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Forenede Stater, 89144
- Suspenderet
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Forenede Stater, 89144
- Suspenderet
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, Forenede Stater, 89148-2405
- Suspenderet
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, Forenede Stater, 89148
- Suspenderet
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Forenede Stater, 89169
- Suspenderet
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Forenede Stater, 89102
- Suspenderet
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Forenede Stater, 89183
- Suspenderet
- OptumCare Cancer Care at Fort Apache
-
Pahrump, Nevada, Forenede Stater, 89048
- Suspenderet
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, Forenede Stater, 89502
- Rekruttering
- Renown Regional Medical Center
-
Ledende efterforsker:
- Seema L. Rao
-
Kontakt:
- Site Public Contact
- Telefonnummer: 775-982-5050
- E-mail: Renown-CRD@renown.org
-
Reno, Nevada, Forenede Stater, 89503
- Suspenderet
- Saint Mary's Regional Medical Center
-
Reno, Nevada, Forenede Stater, 89511
- Suspenderet
- Cancer Care Specialists - Reno
-
-
New Hampshire
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Rekruttering
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Ledende efterforsker:
- Angela Ricci
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-mail: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- Hackensack University Medical Center
-
Ledende efterforsker:
- Jing Chen
-
Kontakt:
- Site Public Contact
- Telefonnummer: 551-996-2897
-
Morristown, New Jersey, Forenede Stater, 07960
- Rekruttering
- Morristown Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-971-5900
-
Ledende efterforsker:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rekruttering
- Rutgers Cancer Institute of New Jersey
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-7356
-
Ledende efterforsker:
- Richard A. Drachtman
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Rekruttering
- Saint Peter's University Hospital
-
Ledende efterforsker:
- Nibal A. Zaghloul
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-745-8600
- E-mail: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rekruttering
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-8675
-
Ledende efterforsker:
- Richard A. Drachtman
-
Newark, New Jersey, Forenede Stater, 07112
- Rekruttering
- Newark Beth Israel Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-926-7230
- E-mail: Christine.Kosmides@rwjbh.org
-
Ledende efterforsker:
- Teena Bhatla
-
Paterson, New Jersey, Forenede Stater, 07503
- Rekruttering
- Saint Joseph's Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-754-2207
- E-mail: HallL@sjhmc.org
-
Ledende efterforsker:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- Rekruttering
- Presbyterian Hospital
-
Ledende efterforsker:
- Beeling Armijo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 505-559-6113
- E-mail: wburman@phs.org
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Rekruttering
- Albany Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 518-262-5513
-
Ledende efterforsker:
- Lauren R. Weintraub
-
Brooklyn, New York, Forenede Stater, 11219
- Rekruttering
- Maimonides Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-765-2500
-
Ledende efterforsker:
- Mahmut Y. Celiker
-
Mineola, New York, Forenede Stater, 11501
- Rekruttering
- NYU Langone Hospital - Long Island
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-263-4432
- E-mail: cancertrials@nyulangone.org
-
Ledende efterforsker:
- Chana L. Glasser
-
New Hyde Park, New York, Forenede Stater, 11040
- Rekruttering
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-470-3460
-
Ledende efterforsker:
- Julie I. Krystal
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Ledende efterforsker:
- Nobuko Hijiya
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-342-5162
- E-mail: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Memorial Sloan Kettering Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-639-7592
-
Ledende efterforsker:
- Kavitha Ramaswamy
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Ledende efterforsker:
- Elizabeth A. Raetz
-
Kontakt:
- Site Public Contact
- E-mail: CancerTrials@nyulangone.org
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- NYP/Weill Cornell Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-746-1848
-
Ledende efterforsker:
- Jaclyn Rosenzweig
-
Rochester, New York, Forenede Stater, 14642
- Aktiv, ikke rekrutterende
- University of Rochester
-
Stony Brook, New York, Forenede Stater, 11794
- Rekruttering
- Stony Brook University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-862-2215
-
Ledende efterforsker:
- Laura E. Hogan
-
Syracuse, New York, Forenede Stater, 13210
- Rekruttering
- State University of New York Upstate Medical University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 315-464-5476
-
Ledende efterforsker:
- Melanie A. Comito
-
The Bronx, New York, Forenede Stater, 10467
- Rekruttering
- Montefiore Medical Center - Moses Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-379-6866
- E-mail: eskwak@montefiore.org
-
Ledende efterforsker:
- Alice Lee
-
-
North Carolina
-
Asheville, North Carolina, Forenede Stater, 28801
- Rekruttering
- Mission Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 828-213-7055
- E-mail: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Ledende efterforsker:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- Rekruttering
- UNC Lineberger Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-668-0683
- E-mail: cancerclinicaltrials@med.unc.edu
-
Ledende efterforsker:
- Thomas B. Alexander
-
Charlotte, North Carolina, Forenede Stater, 28203
- Rekruttering
- Carolinas Medical Center/Levine Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-9376
-
Ledende efterforsker:
- Joel A. Kaplan
-
Durham, North Carolina, Forenede Stater, 27710
- Rekruttering
- Duke University Medical Center
-
Ledende efterforsker:
- Jessica M. Sun
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-275-3853
-
Greenville, North Carolina, Forenede Stater, 27834
- Rekruttering
- East Carolina University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 252-744-1015
- E-mail: eubankss@ecu.edu
-
Ledende efterforsker:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Rekruttering
- Wake Forest University Health Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-713-6771
-
Ledende efterforsker:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Forenede Stater, 58122
- Rekruttering
- Sanford Broadway Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Ledende efterforsker:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44308
- Rekruttering
- Children's Hospital Medical Center of Akron
-
Kontakt:
- Site Public Contact
- Telefonnummer: 330-543-3193
-
Ledende efterforsker:
- Lauren R. Draper
-
Cincinnati, Ohio, Forenede Stater, 45229
- Rekruttering
- Cincinnati Children's Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 513-636-2799
- E-mail: cancer@cchmc.org
-
Ledende efterforsker:
- Erin H. Breese
-
Cleveland, Ohio, Forenede Stater, 44106
- Rekruttering
- Rainbow Babies and Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 216-844-5437
-
Ledende efterforsker:
- Duncan S. Stearns
-
Cleveland, Ohio, Forenede Stater, 44195
- Suspenderet
- Cleveland Clinic Foundation
-
Columbus, Ohio, Forenede Stater, 43205
- Rekruttering
- Nationwide Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-722-6039
- E-mail: Melinda.Triplet@nationwidechildrens.org
-
Ledende efterforsker:
- Mark A. Ranalli
-
Dayton, Ohio, Forenede Stater, 45404
- Rekruttering
- Dayton Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-228-4055
-
Ledende efterforsker:
- Jordan M. Wright
-
Sylvania, Ohio, Forenede Stater, 43560
- Suspenderet
- ProMedica Flower Hospital
-
Toledo, Ohio, Forenede Stater, 43606
- Rekruttering
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 419-824-1842
- E-mail: PCIOncResearch@promedica.org
-
Ledende efterforsker:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- Rekruttering
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Ledende efterforsker:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, Forenede Stater, 74136
- Rekruttering
- Saint Francis Children's Hospital
-
Ledende efterforsker:
- Jill A. Salo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 918-502-6720
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97227
- Rekruttering
- Legacy Emanuel Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-413-2560
-
Ledende efterforsker:
- Jason M. Glover
-
Portland, Oregon, Forenede Stater, 97239
- Rekruttering
- Oregon Health and Science University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-494-1080
- E-mail: trials@ohsu.edu
-
Ledende efterforsker:
- Bill H. Chang
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forenede Stater, 18103
- Rekruttering
- Lehigh Valley Hospital-Cedar Crest
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-402-9543
- E-mail: Morgan_M.Horton@lvhn.org
-
Ledende efterforsker:
- Jacob A. Troutman
-
Danville, Pennsylvania, Forenede Stater, 17822
- Rekruttering
- Geisinger Medical Center
-
Ledende efterforsker:
- Jagadeesh Ramdas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-mail: cancerresearch@geisinger.edu
-
Hershey, Pennsylvania, Forenede Stater, 17033
- Rekruttering
- Penn State Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 717-531-6012
-
Ledende efterforsker:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia
-
Ledende efterforsker:
- Shannon L. Maude
-
Kontakt:
- Site Public Contact
- Telefonnummer: 267-425-5544
- E-mail: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, Forenede Stater, 19134
- Rekruttering
- Saint Christopher's Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-427-8991
-
Ledende efterforsker:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Rekruttering
- Children's Hospital of Pittsburgh of UPMC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-692-8570
- E-mail: jean.tersak@chp.edu
-
Ledende efterforsker:
- Jenny Ruiz
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02903
- Rekruttering
- Rhode Island Hospital
-
Ledende efterforsker:
- Bradley DeNardo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 401-444-1488
-
-
South Carolina
-
Columbia, South Carolina, Forenede Stater, 29203
- Rekruttering
- Prisma Health Richland Hospital
-
Ledende efterforsker:
- Stuart L. Cramer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Forenede Stater, 29605
- Rekruttering
- BI-LO Charities Children's Cancer Center
-
Ledende efterforsker:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Forenede Stater, 29615
- Rekruttering
- Prisma Health Cancer Institute - Eastside
-
Ledende efterforsker:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57117-5134
- Rekruttering
- Sanford USD Medical Center - Sioux Falls
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
Ledende efterforsker:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37916
- Rekruttering
- East Tennessee Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 865-541-8266
-
Ledende efterforsker:
- Susan E. Spiller
-
Nashville, Tennessee, Forenede Stater, 37232
- Rekruttering
- Vanderbilt University/Ingram Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-811-8480
-
Ledende efterforsker:
- Brianna N. Smith
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- The Children's Hospital at TriStar Centennial
-
Kontakt:
- Site Public Contact
- Telefonnummer: 615-342-1919
-
Ledende efterforsker:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Forenede Stater, 78723
- Rekruttering
- Dell Children's Medical Center of Central Texas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 512-628-1902
- E-mail: TXAUS-DL-SFCHemonc.research@ascension.org
-
Ledende efterforsker:
- Shannon M. Cohn
-
Corpus Christi, Texas, Forenede Stater, 78411
- Rekruttering
- Driscoll Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 361-694-5311
- E-mail: Crystal.DeLosSantos@dchstx.org
-
Ledende efterforsker:
- Nkechi I. Mba
-
Dallas, Texas, Forenede Stater, 75390
- Rekruttering
- UT Southwestern/Simmons Cancer Center-Dallas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Ledende efterforsker:
- Tamra L. Slone
-
Dallas, Texas, Forenede Stater, 75230
- Rekruttering
- Medical City Dallas Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 972-566-5588
-
Ledende efterforsker:
- Maurizio L. Ghisoli
-
El Paso, Texas, Forenede Stater, 79905
- Rekruttering
- El Paso Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 915-298-5444
- E-mail: ranjan.bista@ttuhsc.edu
-
Ledende efterforsker:
- Benjamin Carcamo
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- Cook Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 682-885-2103
- E-mail: CookChildrensResearch@cookchildrens.org
-
Ledende efterforsker:
- Kenneth M. Heym
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Ledende efterforsker:
- Anil George
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-798-1354
- E-mail: burton@bcm.edu
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- UT MD Anderson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-632-6789
- E-mail: askmdanderson@mdanderson.org
-
Ledende efterforsker:
- Najat C. Daw
-
Lubbock, Texas, Forenede Stater, 79410
- Rekruttering
- Covenant Children's Hospital
-
Ledende efterforsker:
- Kishor M. Bhende
-
Kontakt:
- Site Public Contact
- Telefonnummer: 806-725-8657
- E-mail: mbisbee@providence.org
-
Lubbock, Texas, Forenede Stater, 79415
- Rekruttering
- UMC Cancer Center / UMC Health System
-
Kontakt:
- Site Public Contact
- Telefonnummer: 806-775-8590
-
Ledende efterforsker:
- Erin K. Barr
-
San Antonio, Texas, Forenede Stater, 78207
- Rekruttering
- Children's Hospital of San Antonio
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-704-2894
- E-mail: bridget.medina@christushealth.org
-
Ledende efterforsker:
- Julie Voeller
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- University of Texas Health Science Center at San Antonio
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-450-3800
- E-mail: phoresearchoffice@uthscsa.edu
-
Ledende efterforsker:
- Anne-Marie R. Langevin
-
San Antonio, Texas, Forenede Stater, 78229
- Rekruttering
- Methodist Children's Hospital of South Texas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-575-6240
- E-mail: Vinod.GidvaniDiaz@hcahealthcare.com
-
Ledende efterforsker:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84113
- Rekruttering
- Primary Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 801-585-5270
-
Ledende efterforsker:
- Luke D. Maese
-
-
Vermont
-
Burlington, Vermont, Forenede Stater, 05405
- Rekruttering
- University of Vermont and State Agricultural College
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-656-8990
- E-mail: rpo@uvm.edu
-
Ledende efterforsker:
- Jessica L. Heath
-
-
Virginia
-
Falls Church, Virginia, Forenede Stater, 22042
- Rekruttering
- Inova Fairfax Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 703-208-6650
- E-mail: Stephanie.VanBebber@inova.org
-
Ledende efterforsker:
- Robin Y. Dulman
-
Norfolk, Virginia, Forenede Stater, 23507
- Rekruttering
- Children's Hospital of The King's Daughters
-
Kontakt:
- Site Public Contact
- Telefonnummer: 757-668-7243
- E-mail: CCBDCresearch@chkd.org
-
Ledende efterforsker:
- Melissa S. Mark
-
Richmond, Virginia, Forenede Stater, 23298
- Rekruttering
- VCU Massey Comprehensive Cancer Center
-
Ledende efterforsker:
- Jordyn R. Griffin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
-
Washington
-
Bellevue, Washington, Forenede Stater, 98004
- Suspenderet
- Overlake Medical Center
-
Renton, Washington, Forenede Stater, 98055
- Suspenderet
- Valley Medical Center
-
Seattle, Washington, Forenede Stater, 98105
- Rekruttering
- Seattle Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-987-2000
-
Ledende efterforsker:
- Sarah E. Leary
-
Spokane, Washington, Forenede Stater, 99204
- Rekruttering
- Providence Sacred Heart Medical Center and Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-228-6618
- E-mail: HopeBeginsHere@providence.org
-
Ledende efterforsker:
- Judy L. Felgenhauer
-
Tacoma, Washington, Forenede Stater, 98405
- Rekruttering
- Mary Bridge Children's Hospital and Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 253-403-1461
- E-mail: research@multicare.org
-
Ledende efterforsker:
- Robert G. Irwin
-
Tacoma, Washington, Forenede Stater, 98431
- Rekruttering
- Madigan Army Medical Center
-
Ledende efterforsker:
- Melissa A. Forouhar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 253-968-6144
- E-mail: melissa.a.forouhar.mil@health.mil
-
Yakima, Washington, Forenede Stater, 98902
- Suspenderet
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Bridgeport, West Virginia, Forenede Stater, 26330
- Suspenderet
- United Hospital Center
-
Charleston, West Virginia, Forenede Stater, 25304
- Rekruttering
- Vandalia Health/CAMC Institute for Academic Medicine
-
Ledende efterforsker:
- Mohamad H. Badawi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-388-9944
- E-mail: CAMCClinicalTrials@vandaliahealth.org
-
Martinsburg, West Virginia, Forenede Stater, 25401
- Suspenderet
- WVUH-Berkely Medical Center
-
Morgantown, West Virginia, Forenede Stater, 26506
- Rekruttering
- West Virginia University Healthcare
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-293-7374
- E-mail: cancertrialsinfo@hsc.wvu.edu
-
Ledende efterforsker:
- Ashley E. Meyer
-
Parkersburg, West Virginia, Forenede Stater, 26101
- Suspenderet
- Camden Clark Medical Center
-
-
Wisconsin
-
Green Bay, Wisconsin, Forenede Stater, 54301
- Rekruttering
- Saint Vincent Hospital Cancer Center Green Bay
-
Ledende efterforsker:
- Catherine A. Long
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-mail: WI_research_admin@hshs.org
-
Madison, Wisconsin, Forenede Stater, 53792
- Rekruttering
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Ledende efterforsker:
- Cathy A. Lee-Miller
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Rekruttering
- Children's Hospital of Wisconsin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-955-4727
- E-mail: MACCCTO@mcw.edu
-
Ledende efterforsker:
- Michael J. Burke
-
-
-
-
-
San Juan, Puerto Rico, 00926
- Rekruttering
- University Pediatric Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 787-474-0333
-
Ledende efterforsker:
- Maria E. Echevarria
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Patients must be >= 1 and < 31 years at time of enrollment
-
Patients must have first relapse of CD19+ B-ALL (relapse blasts must express CD19) in one of the following categories:
- Isolated bone marrow relapse
- Isolated central nervous system (CNS) (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse
- Combined bone marrow with extramedullary relapse in the CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testes
-
Patients with Down syndrome (DS) are eligible in the following categories:
- Isolated bone marrow relapse
- Combined bone marrow with CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse
-
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
- Of note, for patients with developmental delay (e.g., Down syndrome) regardless of age, Lansky scale may be substituted for Karnofsky scale. However, the requirement for ECOG 0-2 remains, regardless of known history of developmental delay
-
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
-
Patients with prior blinatumomab or CD19+ chimeric antigen receptor therapy in the upfront setting will be eligible, provided relapsed lymphoblasts retain CD19 expression
-
Patients must not have had a prior hematopoietic stem cell transplant
-
A single intrathecal chemotherapy at the time of relapse will be allowed. If < 7 days have elapsed between this intrathecal therapy (IT) and the start of protocol therapy, then the day 1 intrathecal chemotherapy (i.e. methotrexate, cytarabine, or triple intrathecal) may be omitted
-
In the 28 days prior to enrollment, up to five days of post-relapse, pre-enrollment therapy (steroids and/or hydroxyurea only) is permissible
- Patients with Down syndrome who received pre-enrollment therapy and have a white blood count (WBC) >= 30,000/ul at the time of enrollment still must receive protocol specified cytoreductive therapy with vincristine and dexamethasone, and no "washout" is required
- Patients with Down syndrome who received pre-enrollment therapy and have a WBC < 30,000/ul at the time of enrollment must be given a 24 hour "washout" before starting immunotherapy
-
Note: There is no waiting period or "washout" for patients who relapse while receiving upfront therapy
-
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/sex as follows (within 7 calendar days prior to enrollment):
-
Age: Maximum serum creatinine (mg/dL)
-
1 to < 2 years: 0.6 (male), 0.6 (female)
-
2 to < 6 years: 0.8 (male), 0.8 (female)
-
6 to < 10 years: 1 (male), 1 (female)
-
10 to < 13 years: 1.2 (male), 1.2 (female)
-
13 to < 16 years: 1.5 (male), 1.4 (female)
-
>= 16 years: 1.7 (male), 1.4 (female)
- The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the Center for Disease Control (CDC)
-
-
-
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by echocardiogram, cardiac magnetic resonance imaging (MRI) or radionuclide angiogram
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
-
Patients with B-lymphoblastic lymphoma (B-LLy)
-
Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia
-
Patients with Philadelphia chromosome positive (Ph+) B-ALL or ABL class Ph-like B-ALL (i.e. rearrangements involving ABL1, ABL2, CSF1R or PDGFRB and predicted to be sensitive to imatinib or dasatinib)
-
Patients with mixed phenotype acute leukemia (MPAL)
-
Patients with known Charcot-Marie-Tooth disease
-
Patients with known MYC translocation associated with mature (Burkitt) B-cell ALL, regardless of blast immunophenotype
-
Patients with active, uncontrolled infection defined as:
- Positive bacterial blood culture within 48 hours of study enrollment
- Receiving IV or PO antibiotics for an infection with continued signs or symptoms. Note: Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection if cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved. For patients with clostridium (C.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline.
- Fever above 38.2 degrees Celsius (C) within 48 hours of study enrollment with clinical signs of infection. Fever without clinical signs of infection that is attributed to tumor burden is allowed if blood cultures are negative for > 48 hours
- A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection
- Active viral or protozoal infection requiring IV treatment
-
Patients known to have one of the following concomitant genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome are not eligible.
-
Patients with uncontrolled HIV, hepatitis B, or hepatitis C infection. Of note, patients with known human immunodeficiency virus (HIV) infection on effective anti-retroviral therapy with undetectable viral load for at least the last 6 months prior to enrollment are eligible. Similarly, hepatitis B and hepatitis C positive patients who have been treated and have no viral detectable burden are also eligible
-
Patients with significant central nervous system pathology that would preclude treatment with blinatumomab, including history of severe neurologic disorder or autoimmune disease with CNS involvement
- Note: Patients with a history of seizures that are well controlled on stable doses of anti-epileptic drugs are eligible Patients with a history of cerebrovascular ischemia/hemorrhage with residual deficits are not eligible. Patients with a history of cerebrovascular ischemia/hemorrhage remain eligible provided all neurologic deficits have resolved
-
Patients with an active known/suspected autoimmune disease are not eligible. However, patients with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
-
Patients with DS patients with known non-hematopoietic, non-CNS/testicular extramedullary disease (i.e., chloromatous disease) are not eligible
- Note: Group 3 and 4 patients with known non-hematopoietic, non-CNS/testicular extramedullary disease (i.e., chloromatous disease) are eligible if this is NOT the only site of relapsed disease
-
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained within 7 days prior to enrollment. Patients who are sexually active and of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of this study. Men with female partners of childbearing potential should use effective contraception during the duration of their treatment. The effect of blinatumomab on fertility has not been evaluated. Blinatumomab is not recommended for pregnant women or women of childbearing potential (WOCBP) not using contraception. Females of reproductive potential must use effective contraception during treatment and for at least 48 hours after the last dose of blinatumomab. Studies in animal models have shown that nivolumab can adversely impair pregnancy. Thus, nivolumab is expected to cause fetal harm during pregnancy. WOCBP receiving nivolumab must continue contraception for a period of at least 5 months after the last dose of nivolumab. It is unknown whether nivolumab is present in breast milk, thus breastfeeding should be discontinued while a patient is receiving nivolumab
-
Lactating females are not eligible unless they agree to not breastfeed their infants. It is unknown whether blinatumomab or its metabolites are excreted in human breast milk. Women are not permitted to breastfeed while receiving blinatumomab and for the last 48 hours after the last blinatumomab dose. Due to the potential for serious adverse reactions in the breastfed infant, women are not permitted to breastfeed during treatment and for 5 months after the last nivolumab dose
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Arm G (dexamethasone, blinatumomab, nivolumab,MTX) DS patients
Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle 2, and MTX IT (for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD <0.01% at the end of Cycle 1 may stop study treatment at the discretion of the treating physician. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo bone marrow aspiration Undergo lumbar puncture
Andre navne:
Given PO or IV
Andre navne:
Given IT
Andre navne:
Undergo blood, urine and cerebrospinal fluid collection
Andre navne:
Given IT
Andre navne:
Given IT, PO, and IV
Andre navne:
|
|
Eksperimentel: Group 1, Arm A (dexamethasone, blinatumomab, MTX)
ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Andre navne:
Given IV
Andre navne:
Undergo bone marrow aspiration Undergo lumbar puncture
Andre navne:
Given PO or IV
Andre navne:
Given IT
Andre navne:
Undergo blood, urine and cerebrospinal fluid collection
Andre navne:
Given IT
Andre navne:
Given IT, PO, and IV
Andre navne:
|
|
Eksperimentel: Group 1, Arm B (dexamethasone, blinatumomab, MTX)
Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo bone marrow aspiration Undergo lumbar puncture
Andre navne:
Given PO or IV
Andre navne:
Given IT
Andre navne:
Undergo blood, urine and cerebrospinal fluid collection
Andre navne:
Given IT
Andre navne:
Given IT, PO, and IV
Andre navne:
|
|
Eksperimentel: Group 2, Arm C (dexamethasone, blinatumomab, MTX)
Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and methotrexate IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Andre navne:
Given IV
Andre navne:
Undergo bone marrow aspiration Undergo lumbar puncture
Andre navne:
Given PO or IV
Andre navne:
Undergo blood, urine and cerebrospinal fluid collection
Andre navne:
Given IT, PO, and IV
Andre navne:
|
|
Eksperimentel: Group 2, Arm D (dexamethasone, nivolumab, blinatumomab, MTX)
Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo bone marrow aspiration Undergo lumbar puncture
Andre navne:
Given PO or IV
Andre navne:
Undergo blood, urine and cerebrospinal fluid collection
Andre navne:
Given IT, PO, and IV
Andre navne:
|
|
Eksperimentel: Group 3, Arm E (dexamethasone, blinatumomab, MTX)
See Outline section |
Undergo bone marrow biopsy
Andre navne:
Given IV
Andre navne:
Undergo bone marrow aspiration Undergo lumbar puncture
Andre navne:
Given PO
Andre navne:
Given IM or IV
Andre navne:
Given IV
Andre navne:
Given PO or IV
Andre navne:
Given IM
Andre navne:
Given IT
Andre navne:
Undergo blood, urine and cerebrospinal fluid collection
Andre navne:
Given IT
Andre navne:
Given IT, PO, and IV
Andre navne:
Undergo 3D-CRT
Andre navne:
Given IV push or via infusion
Andre navne:
|
|
Eksperimentel: Group 3, Arm F (dexamethasone, blinatumomab, nivolumab)
See Outline section |
Undergo bone marrow biopsy
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo bone marrow aspiration Undergo lumbar puncture
Andre navne:
Given PO
Andre navne:
Given IM or IV
Andre navne:
Given IV
Andre navne:
Given PO or IV
Andre navne:
Given IM
Andre navne:
Given IT
Andre navne:
Undergo blood, urine and cerebrospinal fluid collection
Andre navne:
Given IT
Andre navne:
Given IT, PO, and IV
Andre navne:
Undergo 3D-CRT
Andre navne:
Given IV push or via infusion
Andre navne:
|
|
Eksperimentel: Group 4 Arm I (Dexamethasone, blinatumomab, nivolumab)
Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo bone marrow aspiration Undergo lumbar puncture
Andre navne:
Given IV
Andre navne:
Given PO or IV
Andre navne:
Given IT
Andre navne:
Undergo blood, urine and cerebrospinal fluid collection
Andre navne:
Given IT
Andre navne:
Given IT, PO, and IV
Andre navne:
|
|
Eksperimentel: Group 4, Arm H (dexamethasone blinatumomab)
Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
Andre navne:
Given IV
Andre navne:
Undergo bone marrow aspiration Undergo lumbar puncture
Andre navne:
Given PO or IV
Andre navne:
Given IT
Andre navne:
Undergo blood, urine and cerebrospinal fluid collection
Andre navne:
Given IT
Andre navne:
Given IT, PO, and IV
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Minimal residual disease (MRD) negative second remission (Rem-2) rate with blinatumomab vs with blinatumomab + nivolumab (Group 1)
Tidsramme: Up to 2 cycles of therapy (each cycle = 36 days)
|
MRD negative Rem-2 be defined as Rem-2 (i.e., achievement of MRD < 1% blasts by flow cytometry and resolution of extramedullary disease (for CNS disease, requires CNS 1) ) and bone marrow with MRD < 0.01% by flow cytometry. MRD negative Rem-2 rate between Arm A vs Arm B will be compared using a one-sided Z test of proportions with Type I error of 0.10. Interim analysis will be conducted to monitor for futility. The futility boundaries are based on testing the alternative hypothesis at the 0.067 level. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Event-free survival post-reinduction (EFS PR) (Group 3)
Tidsramme: From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Comparison of EFS post reinduction between Arm E versus Arm F will be based on a one-sided two-sample logrank test with Type I error of 0.15, to be conducted 3 years after completion of enrollment of Group 3. Interim analysis will be conducted to monitor for futility. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. This alpha level corresponds to that which would cause futility stopping if the one-sided two-sample logrank test shows evidence of a hazard ratio > 1.0 when half of the expected events are observed. |
From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
|
EFS PR (Group 4)
Tidsramme: From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Comparison of EFS post reinduction between Arm H versus Arm I will be based on a one-sided two-sample logrank test with Type I error of 0.10, to be conducted 3 years after completion of enrollment of Group 3. Interim analysis will be conducted to monitor for futility. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. This alpha level corresponds to that which would cause futility stopping if the one-sided two-sample logrank test shows evidence of a hazard ratio > 1.0 when half of the expected events are observed. |
From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Dose-limiting toxicity
Tidsramme: Up to 1 cycle of therapy (each cycle = 36 days)
|
Will be assessed using the Common Terminology Criteria for Adverse Events version 5.0. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
EFS PR (Group 4)
Tidsramme: From date of randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years after completion of enrollment
|
Comparison of EFS post-reinduction between Arm C versus Arm D will be based on a one-sided two-sample logrank test with type I error of 0.15, to be conducted 2 years after completion of enrollment of Group 2. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. |
From date of randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years after completion of enrollment
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Event-free survival (Group 1)
Tidsramme: From date of Group 1 randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years
|
EFS will be compared between Arm A and Arm B, and to similar patients treated on AALL1331. These analyses will be performed using logrank tests, semi-parametric or parametric survival analysis methods, as appropriate. |
From date of Group 1 randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years
|
|
Event free survival (Group 4)
Tidsramme: From date of Group 4 randomization to date of treatment failure, relapse, SMN or death due to any cause, assessed up to 5 years
|
EFS of Arm H and Arm I will be compared to similar patients treated on AALL1331. These analyses will be performed using logrank tests, semi-parametric or parametric survival analysis methods, as appropriate. Cumulative incidence rates of each EFS event type will also be estimated and presented with cumulative incidence curves, and be compared between groups as appropriate. |
From date of Group 4 randomization to date of treatment failure, relapse, SMN or death due to any cause, assessed up to 5 years
|
|
Incidence of adverse events in Arm A or Arm B
Tidsramme: Up to 1 cycle of therapy (each cycle = 36 days)
|
The toxicities as defined by grade 3 or greater reported adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab will be compared to similar patients treated with Block 1 of cytotoxic chemotherapy on AALL1331 using two-sample test of proportions. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
Incidence of adverse events in Arm H or Arm I
Tidsramme: Up to 1 cycle of therapy (each cycle = 36 days)
|
The toxicities as defined by grade 3 or greater reported adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab will be compared to similar patients treated with Block 1 of cytotoxic chemotherapy on AALL1331 using two-sample test of proportions. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
MRD negative Rem-2 rate (Group 2)
Tidsramme: Up to 2 cycles of therapy (each cycle = 36 days)
|
MRD negative Rem-2 rate will be estimated and be compared between Arm C and Arm D using two-sample test of proportions. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Dose-limiting toxicity (Down syndrome patients)
Tidsramme: Up to 1 cycle of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
Incidence of adverse events (Down syndrome patients)
Tidsramme: Up to 1 cycle of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
MRD negative Rem-2 rate (Down syndrome patients)
Tidsramme: Up to 2 cycles of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Subset analyses of EFS
Tidsramme: Up to 2 cycles of therapy (each cycle = 36 days)
|
Features at first relapse including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count, will be conducted. These analyses will be exploratory. Cumulative incidence rates of each EFS event type will also be estimated and presented with cumulative incidence curves, and be compared between groups as appropriate. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Subset analyses of OS
Tidsramme: Up to 2 cycles of therapy (each cycle = 36 days)
|
Features at first relapse including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count, will be conducted. These analyses will be exploratory. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
EFS PR (Group 4)
Tidsramme: At 2 years from date of randomization
|
Corresponding 95% CIs by sex, by race, and by ethnicity separately for arm H and I. |
At 2 years from date of randomization
|
|
EFS PR (Group 3)
Tidsramme: At 3 years from date of randomization
|
Corresponding 95% CIs by sex, by race, and by ethnicity separately for arm E and F. |
At 3 years from date of randomization
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Stacy L Cooper, Children's Oncology Group
Publikationer og nyttige links
Generelle publikationer
- Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704.
- Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neurologiske manifestationer
- Sygdomme i nervesystemet
- Neoplasmer
- Genetiske sygdomme, medfødte
- Sygdomme i immunsystemet
- Infektioner
- Virussygdomme
- Neoplasmer efter histologisk type
- Neuroadfærdsmæssige manifestationer
- DNA-virusinfektioner
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Medfødte abnormiteter
- Lymfom, B-celle
- Lymfom
- Abnormiteter, multiple
- Intellektuel handicap
- Epstein-Barr-virusinfektioner
- Herpesviridae infektioner
- Tumorvirusinfektioner
- Kromosomlidelser
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Hemiske og lymfatiske sygdomme
- Burkitt lymfom
- Downs syndrom
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovlforbindelser
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Undersøgelsesteknikker
- Terapeutik
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Punkteringer
- Kirurgiske procedurer, operative
- Cytologiske teknikker
- Nukleinsyrer, nukleotider og nukleosider
- Cytodiagnose
- Kulbrinter
- Kulbrinter, cyklisk
- Alkaloider
- Kulbrinter, aromatisk
- Polycykliske forbindelser
- Hydrolaser
- Enzymer
- Enzymer og coenzymer
- Indoler
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Puriner
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Gravidier
- Graviditet
- Steroider
- SMUSED-RING-forbindelser
- Steroider, fluoreret
- Benzenderivater
- Diagnostiske teknikker, kirurgisk
- Sulfonsyrer
- Svovlsyrer
- Nukleosider
- Pterins
- Pteridiner
- Gravideretrioler
- Amidohydrolaser
- Vinca alkaloider
- Secologanin tryptamin alkaloider
- Indole alkaloider
- Indolizidiner
- Indolizines
- Arabinonucleosider
- Aminopterin
- Strålebehandling
- Graviderede
- Gravidser
- 11-hydroxycorticosteroider
- Hydroxycorticosteroider
- Adrenal cortexhormoner
- 17-hydroxycorticosteroider
- Diagnostiske teknikker, neurologisk
- Benzenesulfonater
- Arylsulfonater
- Arylsulfonsyrer
- Strålebehandling, computerassisteret
- Sulfhydrylforbindelser
- Nivolumab
- Dexamethason
- Methotrexat
- Cytarabin
- Vincristine
- Hydrocortison
- Asparaginase
- Mercaptopurin
- Calciumdobesilat
- Biopsi
- Håndtering af eksemplar
- Blinatumomab
- Spinal punktering
- Dexamethason 21-phosphat
- N, N-dicyclohexyl-isoborneol-10-sulfonamid
- Calaspargase Pegol
- Azathiopurin
- Merphos
- Pegaspargase
- Strålebehandling, konform
- auricularum
- Dexamethasonacetat
- asparaginase erwinia chrysanthemi rekombinant
- Hydrocortisonhemisuccinat
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NCI-2020-06813
- U10CA180886 (U.S. NIH-bevilling/kontrakt)
- NCI-2020-06813 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- AALL1821 (Anden identifikator: CTEP)
- AALL1821 (Anden identifikator: Children's Oncology Group)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .